Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE Study of INZ-701 in ENPP1 Deficiency
NCT06739980Phase 2Withdrawn
- Sponsor
- Inozyme Pharma
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of INZ-701 in ENPP1 deficiency, sponsored by Inozyme Pharma. Primary endpoint: Plasma Inorganic Pyrophosphate Concentration at 52 weeks. Planned start Jan 2025; status: withdrawn.
02
Drugs
INZ-701
03
Conditions
ENPP1 deficiency
Beyond the preview
Go deeper on NCT06739980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739980.